---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-105038"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2023-09-29T23:59:59+00:00"
generated_at: "2026-06-10T07:11:09.169089+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics raises ~$300M in private placement for GLP-1 pipeline

## Summary
- Sold 21.6M ordinary shares and 2.4M non-voting ordinary shares at $12.49/share (~$37.47/ADS) for ~$300M gross proceeds.
- Proceeds to fund oral GLP-1R agonist GSBR-1290, next-gen GLP-1/GIPR combo, oral amylin agonist, and operations through at least 2026.
- Closing expected on or about Oct 3, 2023; Jefferies and Leerink act as placement agents with 6% fee.
- Registration statement to be filed within 45 days of closing to register resale of shares.

## SEC filing metadata
- accession: 0001104659-23-105038
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2023-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465923105038/0001104659-23-105038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465923105038/tm2327162d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-105038
- JSON: https://secwatch.observer/filing/0001104659-23-105038.json
- Plain text: https://secwatch.observer/filing/0001104659-23-105038.txt

## Key facts
- Material Agreements
  Structure Therapeutics Inc. entered into Purchase Agreement with certain institutional investors valued at aggregate gross proceeds of approximately $300 million (effective 2023-09-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: aggregate gross proceeds of approximately $300 million
  - Effective: 2023-09-29
  source text: On September 29, 2023, Structure Therapeutics Inc. (the “Company”) entered into a share purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465923105038/0001104659-23-105038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.